No supplier or customer ties in CGTX's filings yet. The map draws only what companies disclose to the SEC; ties named in other companies' filings join as the graph reads them.
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Nothing on the wire mentions CGTX yet. Iris sweeps the public feeds every quarter hour; headlines land here the moment a sweep tags them.
How CGTX has moved on past release days vs its typical ±5.0% day, and how often it closed up. Computed from daily closes — not a forecast.